References
- 1. Knoebl P, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012; 10(4): 622-31. doi: 10.1111/j.1538-7836.2012.04654.x.
- 2. Baudo F, Collins P, Huth-Kühne A, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012; 120(1): 39-46. doi: 10.1182/blood-2012-02-408930.
- 3. Collins P, Baudo F, Knoebl P, et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood 2012; 120(1): 47-55. doi: 10.1182/blood-2012-02-409185
- 4. Tengborn L, Baudo F, Huth-Kühne A, et al. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG 2012; 119(12): 1529-37. doi: 10.1111/j.1471-0528.2012.03469.x.
- 5. van den Berg HM, Gouw SC, van der Bom JG, et al. Factor VIII products and inhibitors in severe hemophilia A. N Engl J Med 2013; 368(15): 1457. doi: 10.1056/NEJMc1301995.
- 6. Collins PW, Palmer BP, Chalmers EA, et al. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. Blood 2014; 124(23): 3389-97. doi: 10.1182/blood-2014-07-580498.
- 7. Calvez T, Chambost H, Claeyssens-Donadel S, et al. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe
- hemophilia A. Blood 2014; 124(23): 3398-408. doi: 10.1182/blood-2014-07-586347.